Cumulative Probability of Developing Colon Cancer in UC Patients

Slides:

Advertisements

Similar presentations

Miguel Regueiro, M.D. Professor of Medicine

Advertisements

Biomarkers Managing IBD

Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.

Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.

Peptic ulcer bleeding Incidence and associated mortality rate.

Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.

End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.

How Should We be Assessing and Documenting Endoscopies in IBD: Incorporating Standard Scoring Systems into Patient Care Gary R Lichtenstein, MD Director,

Ghassan Wahbeh MD Associate Professor, Director IBD Program Seattle Children’s Hospital University of Washington.

Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.

IBD: Issues With Menstruation and Contraception. Menstrual Cycle and Bowel-Pattern Fluctuations Bowel-pattern fluctuation is common during the menstrual.

Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.

Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.

“Antibiotics and corticosteroids: Indications and approaches”

Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor.

1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % P

The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Crohn’s Disease & Mycobacterial Infections Kimberly Persley, MD October 19, 2005.

You Can Never Stop a Biologic

STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.

Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.

Am J Gastroenterol 2010; 105:1820–1829 F1 박재현. Background Background A novel mouse line with defects in both transforming growth factor- β type II receptor.

High frequency of early colorectal cancer in inflammatory bowel disease M W M D Lutgens, F P Vleggaar, M E I Schipper, P C F Stokkers, C J van der Woude,

Prof D BA SILK MD AGAF FRCP Imperial College London St Mary’s Campus

Obesity Trends* Among U.S. Adults BRFSS, 1985

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Bleeding and cancer risk in patients with vascular disease COMPASS Steering Committee and Investigators.

Optimizing Use of Biological Agents in Ulcerative Colitis

Stupp Trial: Improved survival with TMZ Chemotherapy

Volume 154, Issue 3, Pages e18 (February 2018)

Pathways in Managing Ulcerative Colitis

Figure 1 Percentages of patients with first seizure experiencing a recurrent seizure over time This graph is based on a fixed-effect pooled percentage.

PREMIER: Rate of hypertension at 18 months

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

A Better Solution For Cancer Patients With VTE?

Covering the Cover Gastroenterology

Raymond Cross, MD, MS, AGAF Associate Professor of Medicine

Fernando Velayos, Uma Mahadevan

Real-World Evidence in VTE

Illustrations in Ulcerative Colitis

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Volume 153, Issue 3, Pages e16-e17 (September 2017)

Long-term risk of cancer in ulcerative colitis: A population-based cohort study from Copenhagen County Karen V. Winther, Tine Jess, Ebbe Langholz, Pia.

Heat map with two-way hierarchical clustering of genus-summarised microbiota abundance and sample grouping for mucosal and tumour microbiotas from patients.

A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.

Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis John Gubatan, Shuji Mitsuhashi, Talia Zenlea,

Individual patients’ FCP (μg/g) values (n=119).

Preprocedure patient ranking of aspects of their care important for obtaining satisfaction with their colonoscopy experience (1=high, 15=low for importance)

Eligibility criteria for inclusion as an expert Delphi panellist

Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis Shailja C.

Baseline Characteristics of the Study Participants

A, B, C, D show outcome results for individual symptoms using GSRS-IBS scoring system and mean symptom severity scores before and after IBS dietetic management.

Baseline Characteristics of the Patients – Part I

Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis Robert D Odze, Francis A Farraye, Jonathan.

Presentation data from US VICTORY Consortium

Presentation data from US VICTORY Consortium

NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T

© The Author(s) Published by Science and Education Publishing.

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to minimum observed white blood cell.

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.

Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.

IBD: A Comorbidity of PSC

PHOENIX I: PASI 75 Response After 12 Weeks

Decision-Making Analysis for Surveillance

Endoscopic picture of ulcerative colitis with (A) Mayo grade 3 score with friable mucosa and large ulcers. Endoscopic picture of ulcerative colitis with.

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

Macroscopic and radiographic views of right hand of patient 2 during course of treatment. Macroscopic and radiographic views of right hand of patient 2.

Presentation transcript:

Cumulative Probability of Developing Colon Cancer in UC Patients Adapted from Eaden et al. Gut 2001;48:526-35.

Outcome of Mucosal Healing After One Year of Treatment Adapted from Froslie et al. Gastroenterology 2007;133:412-22.

Remission Rate According to Treatment Adherence vs. Non-adherence Risk of recurrence is fivefold greater among non-adherent patients (HR=55; 95% C1, 2.3 – 13.0) Adapted from Kane et al. Am J Med 2003;114:39-43.

Remission Rates at 12 Months Adapted from Panaccione et al. Can J Gastroenterol 2008;22(suppl A):98A, Abstract 80.

Pyramid of Therapy for Ulcerative Colitis